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Abstract 
The photocytotoxicity and photobiochemical properties of the new complex trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)(piperidine)] (5) are compared with its analogue containing the less 
basic and less lipophilic ligand pyridine (4). The log P (n-octanol/water) values were of -1.16 
and -1.84 for the piperidine and pyridine complexes, respectively, confirmed that piperidine 
increases the hydrophobicity of the complex. DFT and TDDFT calculations indicate that 5 
has accessible singlet and triplet states which can promote ligand dissociation when populated 
by both UVA and visible white light. When activated by UVA or white light, both compounds 
showed similar cytotoxic potencies in various human cancer cell lines although their 
selectivity was different. The time needed to reach similar antiproliferative activity was 
noticeably decreased by introducing the piperidine ligand. Neither compound showed cross-
resistance in three oxoplatin-resistant cell lines. Furthermore, both compounds showed similar 
anticlonogenic activity when activated by UVA radiation. Interactions of the light-activated 
complexes with DNA showed similar kinetics and levels of DNA platination and similar 
levels of DNA interstrand cross-linking (ca. 5 %). Also the ability to unwind double stranded 
DNA where comparable for the piperidine analogue (24°, respectively), while the piperidine 
complex showed higher potency in changing the conformation of DNA, as measured in an 
ethidium bromide binding assay. These results indicate that the nature of the heterocyclic 
nitrogen ligand can have subtle influences on both the phototoxicity and photobiochemistry of 
this class of photochemotherapeutic agents.  
 
Keywords 
Platinum azides; cisplatin; photoactivation; cytotoxicity; DNA 
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1. Introduction 
Pt
IV
 diazides have been attracting attention for their potential use as photoactivatable 
drugs in cancer chemotherapy. [1, 2] Such photoactivatable Pt complexes could increase the 
therapeutic effect at the site of the tumour while avoiding systemic toxicity typical of 
traditional Pt anticancer drugs. Towards this end, a number of both cis- and trans-diazide Pt
IV
 
complexes have been synthesized and tested for light-dependent cytotoxicity. Two examples, 
cis,trans,cis-[Pt(N3)2(OH)2(NH3)2], 1, and cis,trans,cis-[Pt(N3)2(OH)2(en)], 2 (Figure 1A),  
have been shown to kill cancer cells in a light-dependent fashion by a mechanism distinctly 
different from that of cisplatin. [3] Structure activity relationships show that all-trans Pt
IV
 
diazides are also active; in fact we have found that compounds 3 and 4 are even more potent 
than their cis,trans,cis isomers when activated by light. [3, 4] Furthermore, when ammine or 
alkyl amine ligands are replaced by pyridine, a 10-fold increase in cytotoxicity is observed 
when the complexes are irradiated with UVA light. [5] This effect could be related to the 
decrease in basicity of the coordinating pyridine compared to an ammine or a primary amine 
ligand. However, introduction of a methyl group at the 2- or 3- position of the pyridine ligand 
leads to a strong decrease in cytotoxicity while a methyl group in the 4- position has little 
effect on activity. [5] Thus, steric effects also appear to play a role in the light activation of 
these photolabile Pt complexes.  
To understand better the influence of ligand basicity, lipophilicity and steric effects on 
the biological activity of this class of trans,trans,trans-[Pt(N3)2(OH)2(NH3)(L)] complexes, 
we have prepared compound 5, a piperidine analogue of trans,trans,trans-
[Pt(N3)2(OH)2(NH3)(pyridine)] (4). Piperidine is more basic and lipophilic than pyridine but 
has a comparable steric bulk to pyridine, with a calculated total area of 156 and 127 Å
2
 and a 
calculated molecular volume of 135 and 109 Å
3
 for piperidine and pyridine, respectively. A 
detailed comparison between the photocytotoxic and photobiochemical properties of 
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complexes 4 and 5 was therefore made to provide insight into structure-activity relationships 
in this class of anticancer complexes. 
Figure 1 
Binding of Pt to DNA is commonly associated with the anticancer activity of cisplatin 
and related analogues. [6, 7] Thus, in addition studying the cytotoxic effects on cancer cell 
lines we have also characterized the interactions between DNA and the photoactivated Pt
IV
 
diazides in order to investigate similarities and differences in binding that might explain some 
of the biological effects of these compounds. 
 
2. Materials and methods 
 
Caution! Although no problems were encountered during this work, heavy metal azides 
are known to be shock-sensitive detonators, therefore it is essential that any platinum 
azide compound is handled with care. 
2.1. Chemicals and cell lines 
Cisplatin was from Chempur (Karlsruhe, Germany). Oxoplatin was a gift of the 
RIEMSER Arzneimittel AG, Germany. Compounds 3 and 4 were synthesized as previously 
described. [3, 4] Stock solutions of cisplatin and oxoplatin were prepared in DMF (Sigma) 
and stored at -20 °C. All culture reagents were obtained from Sigma-Aldrich. 
To investigate the phototoxic potency of the compounds, six different human cancer 
cell lines were used: 5637 (bladder), Kyse-70 (esophageal), SISO (cervix adenocarcinoma), 
DAN-G (pancreatic), A-427 (lung) and HL-60 (acute myeloid leukemia). All cell lines were 
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obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany). A mycoplasma screen was done by using the Hoechst staining 
method and all cell lines where found to be free of mycoplasms. The oxoplatin resistant cell 
lines 5637-OXO, SISO-OXO and Kyse-70-OXO were established by weekly exposures to 
oxoplatin over several months and were resistant to both oxoplatin and cisplatin.  
 
2.2. Light Source 
Luzchem Expo panels (Luzchem Reasearch Inc., Ontario, Canada) were used for 
irradiation. The two Expo panels were accommodated with five fluorescent lamps each, 8 W 
per lamp. UVB radiation was cut off by a filter. The light source was positioned 25 cm away 
from the samples giving an intensity of 0.12 mW/cm
2
. Cool white fluorescent mercury tubes, 
8 W, where used for irradiation with white light (intensity of 0.65 mW/cm
2
). The above 
described set up was used in all cell experiments. All other experiments were irradiated using 
the LZC-4V illuminator (photoreactor) (Lutzchem, Canada) with temperature controller and 
UVA tubes (2 mW/cm
2
; λmax = 365 nm). 
 
2.3. Preparation of 5 
Compound 5 was prepared in a three step synthesis: 
2.3.1.  trans-[PtCl2(NH3)(pip)] 
Piperidine (2.5 mmol, 248 µl) was added to a 4 ml cisplatin (0.200 g, 0.67 mmol) 
suspension in water. After stirring at 75 °C for 120 min, the colorless solution was cooled to 
room temperature and reduced to dryness. HCl (2 M, 4 ml) was added to the resulting white 
solid and stirred at 70 °C for 4 days. The solution was cooled on ice before filtering off the 
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yellow precipitate, washed with ice cold water, ethanol and diethyl ether and dried under 
vacuum. Yield: 87% (202.7 mg) of a yellow powder. 
2.3.2.  trans,trans-[Pt(N3)2(NH3)(pip)] 
Trans-[PtCl2(NH3)(pip)] (0.4 mmol, 150 mg) was suspended in 50 ml H2O. After 
adding AgNO3 (0.8 mmol, 68 mg) the solution was stirred at 60 °C for 24 h in the dark. 
Forming removal of AgCl on a sintered funnel, NaN3 (0.8 mmol, 52 mg) was added to the 
solution. After stirring over-night the volume was reduced to ca. 2 – 4 ml and stored at 4 °C 
for 24 h. The yellow precipitate was filtered off, washed (ice cold water, ethanol, diethyl 
ether) and dried under vacuum. Yield: 80% (122 mg) of a light brown powder. 
2.3.3.  trans,trans,trans-[Pt(N3)2(OH)2(NH3)(pip)] (5) 
To a solution of trans,trans-[Pt(N3)2(NH3)(pip)] (0.315 mmol, 120 mg) in 300 ml 
water, H2O2 (30%, 1.9 mmol, 0.195 µl) was added and stirred in the dark overnight. The 
volume was reduced to ca. 25 ml and filtered off. The volume was then reduced and dry 
acetone was added to precipitate the final product, which was collected by filtration and 
washed with ice cold water, ethanol and diethyl ether. Yield: 76 mg (58%) of a bright yellow 
powder. 
IR-Spectra were recorded with a Nicolet IR-200 Ft-IR from Thermo Scientific. The 
IR-band at 3509 cm
-1
 is assigned to N-H and O-H stretching vibrations. N-H bending 
vibration is present at 1660 cm
-1 
(m) 1598 cm
-1
(w) and 1258 cm
-1
 (m). The azide ligand is 
assigned the band at 2030 cm
-1
. The C-H stretching vibration gives a band at 2949 cm
-1
 (s), C-
H bending at 1448 cm
-1
, and the band at 1078 cm
-1
 is due to C-N stretching vibrations. A band 
at 544 cm
-1
 is assigned to a Pt-N vibration. 
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195
Pt NMR spectra for D2O solutions were recorded on a Bruker 400 NMR (86MHz) 
and were externally referenced to potassium hexachloroplatinate. A chemical shift of 919 ppm 
was found for trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pip)], which agrees with published 
195
Pt 
NMR data for other Pt
IV
 compounds. [8, 9] 
 The identity and purity of compound 5 was further confirmed by LC/MS (Shimadzu 
High Perfomance Liquid Chromatograph/Mass Spectrometer). Calculated m/z for 
[C5H15N8O2Pt]
-
 ([M-H
-
) 414.0971; found 414.0965. HPLC of 5 gave a purity of 97%. 
 The UV-Vis-spectra (Figure 1B), recorded with a Hitachi U-2810 spectrophotometer 
in H2O showed a maximum at λ = 287.5 nm with ε = 15,355 M
-1
cm
-1
. A shoulder was 
observed at 350 nm and a maximum with a weak intensity was found at ca. 420 nm (ε = 115 
M
-1
cm
-1
). 
 
2.4. Measurement of log P 
To determine the partition coefficient (P) the shake flask method was used. Water and 
n-octanol were pre-saturated with n-octanol and water, respectively. Compounds were first 
dissolved in water. Three different ratios of octanol/water were used (e.g. 1:1; 1:2 and 2:1). 
Mixing was done by vortexing for 30 min at room temperature to establish the partition 
equilibrium. To separate the phases, centrifugation was done at 3,000 g for 5 min. The 
platinum concentrations in both phases were determined by flameless atomic absorption 
spectroscopy (FAAS) with a UNICAM 989 QZ spectrometer.  
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2.5. Theoretical calculations 
All calculations were performed with the Gaussian 03 (G03) program [10] employing the 
DFT method, the PBE1PBE [11]
 
functionals. The LanL2DZ basis set [12] and effective core 
potential were used for the Pt atom and the 6-31G**+ basis set [13] was used for all other 
atoms. Geometry optimizations of 5 in the ground state (S0) and lowest-lying triplet state (T1) 
were performed in the gas phase and the nature of all stationary points was confirmed by 
normal mode analysis. For the T1 geometries the UKS method with the unrestricted 
PBE1PBE functional was employed. The conductor-like polarizable continuum model 
method (CPCM) [14] with water as solvent was used to calculate the electronic structure and 
the excited states of 5 in solution. Thirty-two singlet and eight triplet excited states with the 
corresponding oscillator strengths were determined with a Time-dependent Density 
Functional Theory (TDDFT) calculation. [15, 16] The computational results are summarized 
in the Supporting Information.  
 
2.6. Cell growth inhibition with the crystal violet method 
Cells were grown in medium containing 90% RPMI 1640 medium and 10% FCS, 
supplemented with penicillin G (30 mg/l) / streptomycin (40 mg/l) and kept at 37 °C in 
humidified atmosphere of 5% carbon dioxide/air. 
In testing for antiproliferative activity, cells were seeded out in 96-well microtiter 
plates in 100 µl medium at a density of 1000 cells/well. The plates were returned to the 
incubator for 24 h. On the day of testing, the stock solutions of cisplatin (20 mM in DMF) 
were serially diluted two fold in DMF to the desired concentration range, giving a series of 
five dilutions. Compounds 3, 4, and 5 were dissolved in water followed by sterile filtration 
immediately. Stock solutions and the dilutions were directly diluted 500-fold into medium. 
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From the working dilutions, 100 µl aliquots were added to each well. When DMF was the 
solvent, a maximum concentration of 0.1% (v/v) DMF was present.  
Compounds 3, 4, and 5 were preincubated with the cells for 1 h, followed by 
irradiation with white light or UVA λmax = 366 nm for up to 30 min. Lower wavelength UV 
radiation was blocked by a filter for both lamps. Luzchem Expo panels (Luzchem Reasearch 
Inc., Ontario, Canada) were used for irradiation. The light sources were mounted inside on the 
roof of the incubator and positioned 25 cm away from the microtiter plates. The plates were 
incubated for an additional 6 h at 37 °C, then the medium was carefully aspirated off and 
replaced with 200 µl fresh medium. Ninety hours later the culture medium was discarded and 
replaced for 25 min with a 1% glutaraldehyde in PBS solution to fix the cells. The fixing 
buffer was removed and replaced with PBS. Staining was done with a 0.02% solution of 
crystal violet in water. The dye was added to each well and discarded after 30 min of staining, 
followed by 15 min washing in fresh water. The cell-bound dye was redissolved in 70% (v/v) 
ethanol/water and the optical density was measured at λ = 570 nm with an Anthos 2010 plate 
reader (Anthos, Salzburg, Austria). The IC50 values were calculated by a linear least-squares 
regression of the T/Ccorr values versus the logarithm of the added compound concentration 
and extrapolating to the T/Ccorr values of 50 %. [17] This assay was used for all adherent cell 
lines. 
 
2.7. Cell growth inhibition with MTT method 
The MTT assay was used for determining cytotoxicity in the suspension of cancer cell 
line HL-60. Cells were seeded out in 96-well microtiter plates in 50µl medium at a density of 
10,000 cells/well. Dilutions of the compounds in cell culture medium were added directly to 
the cultures after seeding. Pretreatment was for 1 h, irradiation with UVA was for 30 min, 
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followed by a 6 h exposure to the photolyse products. After this time the cells were 
centrifuged at 500 g for 5 min and the cell pellet was resuspended in fresh medium. The cells 
were allowed to grow an additional 42 h before the MTT assay was performed. For the MTT 
assay, 20 µl of a 2.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) aqueous solution was added per well and left in contact with the cells in the incubator 
for 4 h. Prior to measuring the optical density at λ = 570 nm, 100 µl of a 0.04 N hydrochloric 
acid in 2-propanol solution was added to dissolve the crystalline formazane. 
 
2.8. Determination of oxoplatin cross-resistance 
The IC50 values of 4 and 5 were determined in three different oxoplatin-resistant 
human cancer cell lines. The three resistant cell lines were developed in our lab from the wild-
type cell lines. The resistance factor (RF) was calculated as follows:  
 
50 oxoplatin resistant
50 wildtype
( )
( )
IC
RF
IC
         (2) 
 
IC50-oxoplatin resistant represents the IC50 value for the oxoplatin resistant cell line and IC50-wildtype 
stands for the IC50 value for the wild-type line. The IC50 values were determined as described 
above by the crystal violet assay. Resistance is said to occur when the RF value is greater than 
1.5. For comparison, cisplatin and oxoplatin were used.  
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2.9. Clonogenic Assay  
The human cervix adenocarcinoma cell line SISO was used for the in vitro clonogenic 
assay. Cells were seeded in culture flasks and incubated for 24 h. Working solutions of 
cisplatin (in DMF), 4 and 5 (in water) were diluted 1000-fold into the culture medium at five 
serial dilutions. After a preincubation time of 1 h, compounds 4, 5 and control were irradiated 
for 30 min with UVA λmax = 366 nm. Medium was removed after 6 h and cells were washed 
twice with PBS before reseeding the cells in six well plates. The culture plates were stored in 
the dark in an incubator for 10 days. Staining was done with a methylene blue solution (1% in 
water/methanol 1:1) added for 30 min. After washing out excess dye, the plates were allowed 
to air dry before manually counting colonies containing 50 or more cells. The plating 
efficiency (PE) was calculated by: 
 
number of colonies formed
100%
number of cells seeded
PE        (3) 
 
The plating efficiency is defined as the ratio of the number of colonies to the number 
of cells seeded. The surviving fraction (SF), expressed in the terms of PE, is the number of 
colonies that form after treatment relative to the number of cells seeded. 
 
number of colonies formed after treatment
number of cells seeded
SF
PE
      (4) 
 
  
12 
The IC50 values were calculated by a linear least-squares regression of the SF values 
versus the logarithm of the added compound concentration and extrapolating to the SF values 
of 50 %. [18] 
 
2.10. Intracellular accumulation of 4 and 5 in the cancer cell line 5637 and comparison 
to cisplatin 
Cells were grown in 25 cm
2
 cell culture flasks at 37 °C in a 5% carbon dioxide/air 
atmosphere to a density of 2 million cells. The cisplatin stock solution was diluted directly 
into fresh culture medium to a concentration of 50 µM. Solutions of 4 and 5 were freshly 
prepared in water. After sterile filtration, the stock solutions were directly diluted in fresh 
culture medium to 50 µM. The flasks were incubated at 37 °C in the dark. After 1 h, the flasks 
containing 4 and 5 were irradiated for 30 min with UVA λmax = 366 nm. Samples of cisplatin 
were not irradiated. Controls without irradiation were also performed. After irradiation the 
flasks were kept in the dark for defined periods of time. For each time point, a flask was 
removed, the medium was discarded and the cells were washed with ice cold PBS. Cells 
where trypsinated and suspended in fresh PBS. A 0.5 ml aliquot was used to determine the 
cell number with a Coulter Counter Z2 instrument (Beckman-Coulter, Miami, USA). The 
suspension was centrifuged at 5,000 g for 5 min at -20 °C. The supernatant was discarded and 
the pellet washed again with ice cold PBS. After a second centrifugation the pellets were 
frozen at -20 °C until further analysis.  
Immediately after thawing the cells were resuspended in a simulated intestinal fluid 
USP solution and incubated for 15 min at 37 °C to digest the cells. To assure complete 
destruction of the cells, samples were placed in a sonic bath for another 15 min at 37 °C. 
Intracellular platinum concentrations were analyzed by flameless atomic absorption 
  
13 
spectroscopy (AAS) as previously described. [19] The results were expressed in terms of 
ng platinum/1 million cells. 
 
2.11. Polarographic measurement of Pt 
Square wave voltammetry was performed with an EG&G Princeton Applied Research 
Model 384B Polarographic Analyzer. A three-electrode system was used, comprising an 
EG&G PARC Model 303A static mercury drop electrode (medium size) and a Ag/AgCl 
(saturated KC1) reference electrode. All potentials are quoted vs. this reference electrode. 
Parameters for the square-wave voltammetry operation were as follows: -0.5 V initial 
potential, -1 V final potential, , 4 mVs
-1
 scan increment, 1 cm
2
 electrode area, 50 mV pulse 
hight, 100 Hz frequency. The electrolyte solution consisted of 1 part 0.08% formaldehyde in 
1.5 M H2SO4, 1 part 0.008% hydrazine in 1.5 M H2SO4, 2 parts water. 
Solutions of double-helical calf thymus DNA were incubated with 4, 5 or cisplatin at 
the ri value 0.1 in 10mM NaClO4 at 37 ºC (ri is defined as the molar ratio of free platinum 
complex to nucleotides at the onset of incubation with DNA). Immediately after mixing, the 
solutions containing 4 or 5 were irradiated with UV light for 30 min and then placed in the 
dark at 37 ºC. Cisplatin- containing solutions were kept in the dark for the whole incubation 
period. At various time intervals, an aliquot of the reaction mixture was withdrawn and 
assayed by SW-voltammetry for platinum non-bound to DNA.  
 
2.12. Ethidium bromide fluorescence studies with DNA 
In all studies, calf thymus DNA (0.04 mg/ml) was incubated with the platinum 
complex in 10 mM NaClO4 at 37 °C for 24 h. For cisplatin and [PtCl(dien)]Cl, the 
incubations were carried out in the dark. For 4 and 5, samples were irradiated with UVA in 
the presence of DNA for 30 min and then placed in the dark. After 24 h an ethidium bromide 
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(EtBr) solution (containing 0.052 mg/ml EtBr and 0.52M NaCl in water) was added to the 
DNA incubations; the final concentration of EtBr was 0.04 mg/ml, which corresponded to the 
saturation of all intercalation sites of EtBr in DNA at a concentration of 0.01 mg/ml. After 30 
min in the dark at room temperature, fluorescence was measured with a Varian Cary Eclipse 
fluorescence spectrophotometer, equipped with a 0.5 cm quartz cell, with an excitation 
wavelength λ = 546 nm and an emission λ =595 nm. 
 
2.13. Unwinding of negatively supercoiled DNA 
Unwinding of closed circular supercoiled pUC19 plasmid DNA (2,686 bp) was 
analyzed by an agarose gel mobility shift assay. [4] The unwinding angle Φ, induced per one 
molecule bound to DNA was calculated by determining the platinum:base ratio at which the 
complete transformation of the supercoiled to relaxed form of the plasmid was attained. An 
aliquot of the sample was subjected to electrophoresis on a 1% native agarose gel running at 
room temperature in the dark with TAE (Tris–aceate/EDTA) buffer. The voltage was set to 25 
V. The gel was stained with EtBr and analysed by photography by using a transilluminator. 
The mean unwinding angle was calculated by equation 1: 
 
 
b
18
r (c)
           (5) 
 
where σ is the superhelical density and rb(c) is the value of rb (rb is defined as the number of 
molecules of the platinum complex bound per nucleotide residue) at which the supercoiled 
and nicked forms co-migrate. Higher rb values above the point of comigratrion cause an 
increase of migration as positive supercoils are induced. 
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2.14, DNA Interstrand cross-linking 
The levels of interstrand cross-linking by 4, 5 and cisplatin in linear DNA were 
measured with pUC19 plasmid (2,686 bp). Linearization was realized by EcoRI (EcoRI cuts 
once within the pUC19 plasmid). The linear DNA was 3'-end-labeled by means of Klenow 
fragment of DNA polymerase I in the presence of [α-32P]dATP and subsequently incubated 
with platinum complexes. Samples of 4 and 5 were irradiated with the labeled and linearized 
DNA for 30 min with UVA light immediately after mixing. After irradiation the samples were 
stored together with cisplatin in the dark at 37 °C. The rb values ranged for 5 from 0.00003 to 
0.002, for 4 from 0.00005 to 0.001 in 0.01 M NaClO4. To each sample of 10 µl, 1µl of 1 mM 
NaOH and 2 µl of a solution containing 1 mM EDTA, 6.6% sucrose and 0.04% bromophenol 
blue were added. Samples were analyzed for interstrand cross-links by agarose gel 
electrophoresis under denaturing conditions (alkaline 1% agarose gel). The intensities of the 
resulting bands corresponding to single strands, and interstrand cross-linked duplex DNA 
were quantified by means of a Phosphor Imager (Fuji BAS 2500 system, AIDA software). 
The Poisson distribution from the fraction of non-cross-linked DNA in combination with the 
rb values and the fragment size was used to calculate the percentage of interstrand cross links 
(the amount of interstrand CLs per one molecule of the platinum complex bound to DNA), 
see equation 2. 
 
b
ln /100
% 100%
r 5372
ss
IEC         (6) 
 
The number of nucleotide residues in the plasmid pUC19 is 5,372. The fraction of 
DNA molecules corresponding to the non-cross-linked DNA is symbolized with ss, the ration 
of platinum compound to DNA is given by rb. [20, 21] 
 
  
16 
2.15. Statistical analysis 
All cell experiments were independently repeated at least three times. The IC50 values 
along with the respective standard deviations were calculated with the software EXCEL (V 
Microsoft®).  
 
3. Results 
3.1. Synthesis of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pip)] 
 The synthesis of 5 was carried out by a method analogous to that used to synthesize 4. 
[3] The new complex was characterized by LC-MS/MS, UV-Vis (Figure 1B), IR and 
195
Pt-
NMR. Because heavy metal azido complexes in general can undergo temperature-sensitive 
detonation, melting point determination and elemental analysis were not preformed. The 
analytical data are consistent with the structure of 5. 
 
3.2. Log P determinations 
  The log P value plays an important role in ADME studies (Absorption, Distribution, 
Metabolism and Excretion) and drug discovery. [22] The traditional shake flask method was 
used to measure the partition coefficient (P) between n-octanol and water.  
The log P value of -2.21 ± 0.08 we obtained for cisplatin is within the range reported 
in the literature; i.e., -2.19 and -2.53. [23-26] This value was constant irrespective of whether 
chloride (100 mM) was present or not. Complexes 4 and 5 are expected to be inert and very 
stable in water. The log P for the trans diammine complexe 3 was found to be -2.51 ± 0.14 
and is thus even more hydrophilic than cisplatin. For 4 and 5 the log P are -1.84 ± 0.06 and -
1.16 ± 0.03, respectively. These results are consistent with the order of the log P values of the 
respective amine ligands: pyridine (0.65) < piperidine (0.84) [27, 28], but the relative 
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difference is greater for the Pt complexes than would be expected from the amine ligands 
alone.  
 
 
3.3. Theoretical calculations 
Thirty-two singlet excited state transitions were calculated by TDDFT to assign the 
experimental bands in the UV-Vis spectrum of complex 5. [29] A good agreement between 
experimental and theoretical spectra was found, although a small blue shift (ca. 20 nm) is 
present in the calculated spectrum (Figure 1B). The absorption at  = 278 nm and the 
shoulder at 350 nm in the experimental data are correctly described by the calculations, as 
well as the low intensity absorption band at ca. 420 nm. The main band in the UV region is 
composed by ligand-to-metal charge transfer (LMCT) transitions with N3
–
, OH
–
 → Pt 
character. The shoulder has a major inter-ligand (IL) nature, while the lower energy 
transitions have a mixed LMCT/IL character. All the described transitions have dissociative 
nature towards the coordinated ligands since they have dominant contributions from the 
strongly σ*-antibonding LUMO and LUMO+1 orbitals. [30] 
Calculation of the lowest-lying triplet geometry can be highly informative [31-33] 
about the photochemistry of metal complexes. Such a state is generally populated in d
6
-metal 
complexes upon excitation and subsequent intersystem-crossing. [5] 
As already observed for other Pt
IV
-azides derivatives, the lowest-lying geometry of 5 
is highly distorted (see supporting information). [30] In fact, the two Pt–N3 bond distances are 
elongated by 0.29 Å and 0.42 Å compared to the ground state geometry, possibly indicating 
that release of azide ligands can occur via triplet formation. 
Interestingly, in the triplet geometry the Pt center displays a significantly lower 
positive charge with respect to the ground state. Such behavior is consistent with the reduction 
from Pt
IV
 to Pt
II
 observed for Pt
IV
-azido complexes. 
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3.4. Influence of light on the cytotoxicity of Pt
IV
-diazides 
The human bladder cancer cell line 5637 was used to study the time-dependent effects 
of irradiation with UVA of 3, 4 and 5 on cells. A microtiter assay based on cell staining with 
crystal violet was used for these studies with adherent cell lines. [34] The MTT assay was 
used for the suspension cell line HL-60. Cell growth was not influenced by the UV 
irradiation. In the dark, all three Pt
IV
-diazide compounds show only weak cytotoxicity. 
(Figure 2A) Irradiation with light of λmax = 366 nm by means of UVA lamps mounted in the 
ceiling of the cell incubator (UVB light was cut off by a filter) caused an increase of the 
cytotoxic potential. Complex 3 was less active than 4 and the piperidine analog 5, while the 
latter two complexes show comparable cytotoxic potential. (Figure 2B) The increased 
potency of trans complexes compared to their cis isomers has been reported earlier. [5] In the 
following experiments 3 was not investigated further due to the comparatively low activity. 
 
Figure 2 
 
 To determine the cytotoxic selectivity of 4 and 5, their IC50 values were determined in 
six different human cancer cell lines.(Table 1) The values for 4 range from 30 µM in a human 
bladder cancer cell line 5637 to 68 µM in a pancreas carcinoma cell line DAN-G. In case of 5, 
the IC50 values range from 20 µM in the acute myeloid leukemia cell line HL-60 to 80 µM in 
the esophageal cell carcinoma line Kyse 70. Thus, 5 shows a 4-fold difference in selectivity 
while 4 only a 2-fold difference between the six cell lines, indicating more selective 
cytotoxicity of the piperidine complex 5. Table 1 also shows that compared to cisplatin, the 
potency of the light-activiated PtIV complexes is 10-20 fold less under identical test 
conditions (i.e., 30 min irradiation, then 6 h exposure to drug followed by 90 h cell growth 
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without drug). However, cisplatin showed the same potency in both the light as in the dark, 
while 4 and 5 are only active when irradiated for 30 min.  
 Table 1 
In studies designed to measure the optimal duration of irradiation, it was found that 
compound 5 is more rapidly activated than 4; i.e., only a 10 min irradiation with UVA is 
required to activate 5 to the same antiproliferative activity as a 30 min irradiation of 4. 
(Figure 3) This effect was noticeable with both UVA and white light. Thus the introduction 
of the piperidine ligand leads to a compound that is more efficiently activated by light.  
Figure 3 
 The use of UVA radiation in a therapeutic context is less desirable than longer 
wavelength light due to the low penetration of UVA into tissue. [35, 36] In order to reach 
deeper laying tumor tissues, light with longer wavelength is required. Thus, the activation of 4 
and 5 was studied with white fluorescent light. Table 1 shows that the IC50 values are up to 
2.5-fold higher in some cell lines when irradiated with white light compared to the UVA. 
Thus, white fluorescence light can also be used to activate both 4 and 5, and the cytotoxic 
potency is only marginally decreased.  
 Treatment with anticancer drugs, e.g. cisplatin and oxoplatin (cis,trans,cis-
[Pt(N3)2(OH)2(NH3)2]), often leads to acquired resistance. However, photoactivatable trans-
Pt
IV
 diazides might be expected to act by a different mechanism than traditional Pt
II
 
complexes. Thus, we investigated whether the new Pt-based drugs can overcome acquired 
resistance to oxoplatin, a cisplatin Pt
IV
 prodrug, [37] in three oxoplatin resistant cell lines 
(SISO, KYSE70, 5637). In these cell lines cisplatin is cross resistant to oxoplatin (2- to 3.4-
fold resistant). This is consistent with the hypothesis of oxoplatin being a prodrug of cisplatin. 
On the other hand, 4 and 5 did not show any cross resistance to oxoplatin. (Table 1) 
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3.5. Clonogenic assay in the human cervix adenocarcinoma cancer cell line SISO 
 The clonogenic assay is an in vitro cell survival assay based on the ability of a single 
cell to grow into a colony and is used to determine cell reproductive death after treatment with 
cytotoxic agents or ionizing radiation. It represents a more appropriate method than a simple 
antiproliferative assay to predict antitumor activity. [18, 38] With the SISO human cervix 
cancer cell line, which grows in well defined colonies, compound 4 is ca. 10-fold more potent 
in the clonogenic assay compared to the antiproliferation assay (IC50 values of 4.94 ± 2.76 and 
43.4 ± 23.7 µM, respectively). Compound 5 shows comparable results and is ca. eight fold 
more potent in the clonogenic than in the antiproliferative assay (values of 5.31 ± 2.84 and 
41.8 ± 3.75 µM, respectively). As expected, cisplatin shows potent anticlonogenic activity 
with an IC50 value of 0.20 ± 0.02 µM. Thus, photoactivated compounds 4 and 5 are ca. 25-
fold less potent in this assay compared to cisplatin but have antitumor potential and have little 
toxicity in the dark, in contrast to cisplatin. 
 
3.6. Cellular uptake rates of Pt by 5637 human bladder cancer cells treated with 4, 5 
and cisplatin. 
Cellular uptake of Pt was studied by FAAS for compounds 4 and 5 in comparison to 
cisplatin. Cells treated with either Pt
IV
 compound in the dark accumulated only very small 
amounts of platinum over 8 h while cells exposed to the same concentrations of cisplatin 
show a continuous uptake of Pt. (Figure 4) When the Pt
IV
 compounds are activated by UVA 
radiation (λmax = 366 nm) for 30 min (indicated by an arrow in Figure 4), rapid uptake of Pt 
takes place. Cells were irradiated for 30 min as in the antiproliferative activity studies. The 
highest level of Pt (40 ng platinum/1 million cells) is reached after ca. 4 h for 4 and after 
about 6 h for 5, respectively. After this time point, a plateau is reached and the cells 
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accumulate no more platinum. Cells treated with cisplatin show no sign of a plateau after 8 h 
while accumulating roughly the same levels of Pt compared to the light activated Pt
IV
 
compounds. 
Figure 4 
 
3.7. Irreversible DNA binding of Pt 
Much evidence exists to implicate the binding of cisplatin to DNA as at least one 
mechanism of anticancer activity. Previous work has shown that 4 can also bind irreversibly 
to calf thymus DNA when activated by light. [3] Thus, we investigated the effect of the 
piperidine ligand in comparison to pyridine ligand on the kinetics of binding of UVA 
activated Pt diazides to calf thymus DNA. Polarography was used to measure the binding of 
platinum to calf thymus DNA as described elsewhere. [39] 
The half-life for cisplatin binding to DNA was found to be 180 min at 37 °C and 24 h; 
a maximum level of DNA platination of 89% was reached after 24 h (Figure 5A). On the 
other hand, no irreversible binding of either 4 or 5 to DNA was observed when incubations 
where done in the dark. Interestingly, UVA activated 4 and 5 (i.e., irradiation of complexes 
for 30 min with light  = 366 nm) both bind much faster to calf thymus DNA than cisplatin 
(Figure 5 B and C); for the UVA-activatable platinum complexes the half-life of binding is 
less than 5 min. After 25 min a plateau is reached for both complexes, with final levels of 
platination being very similar for the two compounds; i.e., 86 and 78% for 4 and 5, 
respectively. 
 
Figure 5 
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It has been reported that extracellular concentrations of chloride (e.g. 100 mM) can 
protect DNA from platination by cisplatin. [40] Likewise, we found that when 100 mM 
chloride was present in the solutions of DNA, very little platination took place with UVA-
activated 4 and 5.  Due to the high chloride concentration, the equilibrium between chlorido 
and aqua Pt
II
 species is shifted towards the less reactive chlorido species. When cisplatin 
enters the cell the chloride concentration drops to 4 – 20 mM and the equilibrium shifts to 
aqua species that bind irreversibly to DNA. Because the same inhibitory effect of chloride 
was observed with 4 and 5, it would appear that UVA-activation also leads to the formation of 
reactive aqua species that can bind irreversibly to DNA.  
 
3.8. Characterization of DNA adducts by ethidium bromide fluorescence. 
The fluorescent dye ethidium bromide (EtBr) can be used to distinguish between 
perturbations induced in DNA by monofunctional and bifunctional adducts of platinum 
compounds. [41] Binding of EtBr to DNA by intercalation is blocked in a stoichiometric 
manner by formation of the bifunctional adducts of a series of platinum complexes including 
cisplatin and transplatin, which results in a loss of fluorescence intensity. [41, 42] On the 
other hand, modification of DNA by monofunctional platinum complexes such as 
[PtCl(dien)]Cl (having only one leaving ligand) only results in a slight decrease of EtBr 
fluorescence intensity as compared with nonplatinated DNA-EtBr complex. 
Double-helical DNA was first modified with nonirradiated cisplatin, [PtCl(dien)]Cl 
and light activated complexes 4 and 5 (for 24 h). The levels of the modification corresponded 
to the values of rb in the range between 0 – 0.1. Modification of DNA by all platinum 
complexes resulted in a decrease of EtBr fluorescence (Figure 6). In accordance with the 
results published earlier [41-43], monofunctional [PtCl(dien)]Cl only decreased the 
fluorescence to a small extent. On the other hand, the decrease induced by the DNA adducts 
of bifunctional cisplatin, and UVA-activated complexes 4 and 5 was considerably more 
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pronounced. This result suggests that upon irradiation 4 and 5 forms DNA adducts which 
cannot be grouped, from the viewpoint of their capability to inhibit EtBr fluorescence, with 
those formed by ”classical” monofunctional platinum(II) complexes. The fact that the 
decrease of EtBr fluorescence induced by the adducts of UVA activated 4 and 5 was even 
noticeably more pronounced than that induced by the adducts of cisplatin (Figure 6) deserves 
further discussion. We suggest that the piperidine or pyridine ligand in all or in a significant 
fraction of adducts of irradiated 4 and 5 (mono- and/or bifunctional) might be well positioned 
to interact with the duplex. The extent of the observed decrease in EtBr fluorescence indicates 
that the disturbance of the DNA helical structure by UVA activated 4 and 5 is not only an 
effect of covalent platinum binding but has to be explained with an additional, perhaps 
intercalative binding mode. The idea that the piperidine or pyridine ligand in the DNA 
adducts of UVA activated 4 and 5 interacts with the duplex is further corroborated by the 
results of DNA unwinding experiments (see the section DNA unwinding). 
Figure 6 
 
3.9. DNA unwinding 
 Electrophoresis in native agarose gel is used to determine the unwinding induced in 
negatively supercoiled pUC19 plasmid by monitoring the degree of supercoiling. [44] A 
compound that unwinds the DNA duplex reduces the number of supercoils in closed circular 
DNA so that their number decreases. This decrease upon binding of unwinding agents causes 
a decrease in the rate of migration through agarose gel, which makes it possible to observe 
and quantify the unwinding.  
 Figure 7 shows electrophoresis gels from experiments in which variable amounts of 
cisplatin and UVA activated 4 or 5 have been bound to a mixture of relaxed and negatively 
supercoiled pUC19 DNA. The unwinding angle is given by Φ = -18 σ/rb(c), where σ is the 
superhelical density and rb(c) is the value of rb at which the supercoiled and relaxed forms 
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comigrate.[44] Under the present experimental conditions, σ was calculated to be -0.040 on 
the basis of data for cisplatin, for which the rb(c) was determined in this study based on the 
value σ = 13°. [44, 45] For UVA activated 4 and 5, rb(c) was 0.03 (Error! Reference source 
not found.B, C, lanes 0.03). The unwinding angle for UVA-activated 4 and 5 calculated in 
this way was 24  1°, respectively. This unwinding angle is considerably greater than that 
found for cisplatin. It is reasonable to suggest that the large additional contribution to 
unwinding is associated with intercalation of the piperidine or pyridine ligands. Thus, the 
large unwinding angle produced by light activated 4 and 5 is good evidence that the pyridine 
or piperidine ligand substantially interacts with duplex DNA upon coordiative binding of 
platinum. In other words, the unwinding angles observed for irradiated 4 and 5 are consistent 
with DNA binding that involves a combined intercalation/coordination mode similar to that 
observed for some cationic platinum(II) complexes that carry ethidium [44] or quinoline [46] 
as a nonleaving group (ethidium and quinoline are well known DNA intercalators which 
extensively unwind DNA).  
Figure 7 
The DNA unwinding of the monofunctional, cationic complexes 
cis-[Pt(NH3)2Cl(N3/N8-ethidium)]
+
 was shown to be 19° and 15° for the N8 and N3 linkage 
isomers, respectively. In contrast, the unwinding by trans-[Pt(NH3)2Cl(N8-ethidium)]
+
 was 
only 8°.[44] Complexes containing intercalators, such as cis-[Pt(NH3)2Cl(N3/N8-ethidium)]
+
 
[44], cis-[Pt(NH3)2Cl(N9-9-aminoacridine)]
+
 and cis-[Pt(NH3)2Cl(chloroquine)]
2+
 [47], form 
adducts on DNA that produce a situation analogous to monofunctional adducts of irradiated 4 
and 5, i. e., a binding mode compatible with both covalent guanine-N7 binding and 
intercalation/stacking of the planar ligand cis to the binding site. Coordination of 
trans-[Pt(NH3)2Cl(N8-ethidium)]
+
 to DNA positions the ethidium ligand trans to the covalent 
binding site and directed away from the double helix. In such a binding mode there is very 
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little contribution from ethidium intercalation to the duplex unwinding. These results and our 
findings are in accordance with the view that the intercalating moiety needs to be cis to the Pt-
N7 bond in order to effectively interact with the DNA base stack. The analogy between the 
above-mentioned cationic cis-complexes and irradiated 4 and 5 based on geometric 
considerations suggests that also monofunctional DNA adducts of the latter compounds may 
significantly contribute to the unwinding of supercoiled DNA. 
 
3.10. DNA interstrand cross-linking.  
 The results of previous work indicate that bifunctional platinum compounds form on 
DNA various types of intrastrand and interstrand cross-links. We also determined in the 
present work interstrand cross-linking frequency of irradiated 4 and 5 observed for the 
platination of natural, high-molecular mass DNA. In these experiments pUC19 plasmid 
(2,686 bp) was used, which was modified by UVA activated 4 or 5 after it had been linearized 
by EcoRI (EcoRI cuts only once within pUC19 plasmid). The sample was analyzed for the 
interstrand cross-links by agarose gel electrophoresis under denaturing conditions. In gel 
electrophoresis experiments under denaturing conditions, 3'-end labeled strands of linearized 
pUC19 plasmid containing no interstrand cross-links migrates as a 2,686-base single strand 
(ss), whereas the interstrand cross-linked strands (ICL) migrate more slowly as a higher 
molecular mass species. The bands corresponding to more slowly migrating interstrand-cross-
linked fragments were clearly noticed if UVA activated 4 or 5 was used to modify DNA 
fragment at rb as low as 1 x 10
-3
 (Figure 8). For comparative purposes, the bands 
corresponding to the modification by cisplatin at rb = 0.001 under identical conditions are also 
shown (Figure 8, lane CDDP). The intensity of the more slowly migrating band increased 
with the growing level of the modification by 4 or 5 with a concomitant decrease in the 
intensity of the band corresponding to the non-cross-linked single strand. The radioactivity 
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associated with the individual bands in each lane was measured to obtain estimates of the 
fraction of non-cross-linked and cross-linked DNA. The frequency of interstrand cross-links 
{the amount of interstrand cross-links per one molecule of 4 or 5 bound to DNA} was 
calculated using the Poisson distribution in combination with the rb values and the fragment 
size. [48] The results indicate that light activated 4 and 5 show a similar interstrand cross-
linking efficiency (6%) as cisplatin. [20]  
Figure 8 
4. Discussion 
To study the chemical and biological effects of a piperidine versus a pyridine ligand in 
trans-diazido Pt
IV
 complexes, trans,trans,trans-[Pt(N3)2(OH)2(NH3)(piperidine)] (5) was 
prepared. The negative octanol/water log P values determined for both 4 and 5 show the 
compounds to be overall hydrophilic, but 5 is noticeably less hydrophilic than 4. This 
difference might be expected to affect the biological properties of the compound (e.g., uptake 
and distribution in cells). 
 Both compounds have only weak antiproliferative activity in the dark but are 
selectively activated by either UVA or visible light to potent phototoxins. The UV-Vis 
spectrum of 5 shows a weak absorption at  = 420 nm, which corresponds to the HOMO → 
LUMO and HOMO–1 → LUMO transitions in the calculated electronic spectra. The singlet 
states accessible through UVA and visible light excitation have all dissociative nature and so 
has the lowest-lying triplet state. This is related to the contribution of the σ*-antibonding 
LUMO and LUMO+1 to all transitions. The population of such orbitals is likely to cause 
ligand dissociation processes.  
When activated by either UVA or white light, 4 and 5 show comparable 
antiproliferative activities across six cancer cell lines, indicating a relatively non-specific 
mechanism of action. In oxoplatin resistant cell lines, neither 4 nor 5 showed cross-resistance 
to oxoplatin (a pro-drug for cisplatin). This may be indicative of a different mechanism of 
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action for the trans-diazido complexes compared to cisplatin. So far no in vivo antitumor data 
for these complexes exist, but the positive results of the clonogenic assay indicate that this 
class of compounds may well have antitumor activity.  
Compared to cisplatin, 4 and 5 had a 10-20 fold lower potency to inhibit cell growth 
when the cells are incubated 6 h with the platinum complexes following light activation. 
While this is a drastic reduction in activity compared to cisplatin, the clinically used analog of 
cisplatin, carboplatin, also shows 10-fold greater IC50 values compare to cisplatin in our cell 
lines. [34] However, carboplatin shows reduced side-effects compared to cisplatin, making it 
a useful therapy for cancer. Thus, not the absolute potency is critical for anticancer activity 
but rather width of the therapeutic index, and light activated platinum complexes would be 
expected to have a wider therapeutic index than platinum complexes that are not selectively 
activated. 
One possible advantage of 5 over 4 could be that the former requires less irradiation to 
reach the same level of antiproliferative activity as the latter. This may be due to the lower 
hydrophilicity of 5 compared to 4, which might allow it to cross cell membranes more rapidly. 
However, Pt uptake studies showed that neither 4 nor 5 are taken up to any appreciable 
amount by cells in the dark. When both are UVA-activated, the rate of uptake of platinum by 
5637 cells is similar for 4 and 5. This indicates that the photolysis products are selectively 
taken accumulated by cells while the starting complexes are not. Cisplatin, in contrast, is 
taken up by cells in the dark to roughly the same levels as light-activated 4 and 5 after 6 h, but 
shows no signs of plateauing after this time as 4 and 5 did. Likewise, cisplatin showed no 
difference between antiproliferative potency in the dark or with UVA irraditation. 
 Like cisplatin both compounds are able to bind irreversibly to DNA after they are 
photoactivated. This finding suggests that DNA could be one of the targets for the cytotoxic 
activity, but does not rule out others. UVA irradiation of either 4 or 5 brings about a very 
rapid platination calf thymus DNA compared to cisplatin; i.e., cisplatin has a half-life of 
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binding of ca. 180 min, while for 4 and 5 the half-life of binding is less than 5 min. A fast 
binding mechanism was also described previously for 4 [3], suggesting a novel mechanism of 
binding Pt to DNA. Nevertheless, the addition of chloride to the DNA solutions prevented 
binding of Pt to DNA, providing evidence that, like cisplatin, Pt-aqua species are 
intermediates in the pathway to DNA platination. Moreover, both 4 and 5 showed a similar 
interstrand-cross-linking efficiency (ca. 5%) compared to cisplatin (ca. 6%), suggesting that 
the main interactions with DNA are either monofunctional adducts or intrastrand crosslinks. 
Interstrand crosslinks would be expected to displace ethidium bromide from its intercalation 
sites in B-DNA and indeed this is observed with both 4 and 5. The intrastrand crosslinks 
caused by cisplatin are known to result in the unwinding of super coiled, double stranded 
DNA, and indeed this was also observed to an even greater extent with both 4 and 5. Thus, the 
evidence on interactions with DNA strongly suggests that intrastrand crosslinks are important 
binding modes for both 4 and 5.  
 Nevertheless, the data for three oxoplatin resistant cell lines show no cross-resistance 
with 4 and 5, which is inconsistent with the Pt species arising from photolysis acting in a 
similar way to cisplatin. Alternative mechanisms of cytotoxicity could involve the release of 
highly reactive azide radicals, which could bring about lipid peroxidation of cell membranes, 
nitrenes or involve attack on proteins. Further data are needed to verify this idea. 
 In conclusion, by substituting the pyridine ligand with piperidine a photoactivatable 
Pt
IV
 diazide was obtained that is less hydrophilic and has a more rapid rate of light activation 
to cytotoxic species. However, in all other cellular and biochemical aspects (e.g., cellular 
uptake, kinetics of DNA platination, DNA crosslinks, DNA unwinding, ect.) the behavior of 
the piperidine complex is similar to that of the pyridine analogue. Thus, the steric bulk of the 
ligand, not the base strength, appears more important for activity of this new class of 
photoactivatable anticancer agents. 
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